Diabetes mellitus is a widespread cluster of metabolic dysfunctions characterized by hyperglycemia resulting from insulin resistance, inadequate insulin secretion, or excessive glucagon secretion. The global diabetes prevalence in 2021 is estimated to be 10.7% (537 million people). Cardiovascular disease (CVD) commonly accompanies diabetes and represents a leading cause of morbidity and mortality worldwide. An increasing body of evidence demonstrates a pivotal role of non-coding RNAs (ncRNAs) in the initiation and progression of both diabetes and CVD. The major classes of ncRNAs implied in diabetes and cardiovascular pathologies are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). The lncRNAs represent a group of diverse molecules that are shown to regulate gene expression and serve as precursors of highly conserved, single-stranded miRNAs involved in crucial physiological processes such as human growth and development, cell proliferation, apoptosis, and metabolism.
Considering that diabetes and CVD are reaching epidemic proportions worldwide, the development of novel diagnostic and therapeutic strategies that efficiently identify and treat complications associated with these diseases is necessary. Because of their role in maintaining physiological homeostasis through the regulation of expression of various genes, miRNAs and lncRNAs attract considerable scientific interest as biomarkers for diagnosis and potential therapeutic agents in diabetes and cardiovascular conditions. This Research Topic will address the problem of the steadily increasing prevalence of diabetes and CVD globally by providing a comprehensive and up-to-date summary of various regulatory ncRNAs involved in these conditions. We encourage discussion regarding the evaluation of ncRNAs as prognostic biomarkers and therapeutic tools for diabetes and cardiovascular diseases. We believe that the recent findings of many studies using novel, high-throughput methodologies for identifying ncRNAs involved in diabetes and CVD necessitate a systematic approach in reviewing and summarizing their roles and potential diagnostic and therapeutic applications.
Some of the specific themes that we would like for contributors to address are:
• Role of miRNAs as endocrine signaling molecules involved in the regulation of insulin production and fat metabolism
• Dysregulation of specific miRNAs that can contribute to metabolic abnormalities
• The molecular cascade of events leading to cardiovascular disorders, emphasizing the role of ncRNAs in their pathophysiology
• Use of miRNAs as potential therapeutic targets for the treatment of diabetes and cardiovascular diseases
We are interested in publishing review and original research articles.
Diabetes mellitus is a widespread cluster of metabolic dysfunctions characterized by hyperglycemia resulting from insulin resistance, inadequate insulin secretion, or excessive glucagon secretion. The global diabetes prevalence in 2021 is estimated to be 10.7% (537 million people). Cardiovascular disease (CVD) commonly accompanies diabetes and represents a leading cause of morbidity and mortality worldwide. An increasing body of evidence demonstrates a pivotal role of non-coding RNAs (ncRNAs) in the initiation and progression of both diabetes and CVD. The major classes of ncRNAs implied in diabetes and cardiovascular pathologies are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). The lncRNAs represent a group of diverse molecules that are shown to regulate gene expression and serve as precursors of highly conserved, single-stranded miRNAs involved in crucial physiological processes such as human growth and development, cell proliferation, apoptosis, and metabolism.
Considering that diabetes and CVD are reaching epidemic proportions worldwide, the development of novel diagnostic and therapeutic strategies that efficiently identify and treat complications associated with these diseases is necessary. Because of their role in maintaining physiological homeostasis through the regulation of expression of various genes, miRNAs and lncRNAs attract considerable scientific interest as biomarkers for diagnosis and potential therapeutic agents in diabetes and cardiovascular conditions. This Research Topic will address the problem of the steadily increasing prevalence of diabetes and CVD globally by providing a comprehensive and up-to-date summary of various regulatory ncRNAs involved in these conditions. We encourage discussion regarding the evaluation of ncRNAs as prognostic biomarkers and therapeutic tools for diabetes and cardiovascular diseases. We believe that the recent findings of many studies using novel, high-throughput methodologies for identifying ncRNAs involved in diabetes and CVD necessitate a systematic approach in reviewing and summarizing their roles and potential diagnostic and therapeutic applications.
Some of the specific themes that we would like for contributors to address are:
• Role of miRNAs as endocrine signaling molecules involved in the regulation of insulin production and fat metabolism
• Dysregulation of specific miRNAs that can contribute to metabolic abnormalities
• The molecular cascade of events leading to cardiovascular disorders, emphasizing the role of ncRNAs in their pathophysiology
• Use of miRNAs as potential therapeutic targets for the treatment of diabetes and cardiovascular diseases
We are interested in publishing review and original research articles.
